PLoS ONE (Jan 2018)

Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia.

  • Kelly D Getz,
  • Tamara P Miller,
  • Alix E Seif,
  • Yimei Li,
  • Yuan-Shung V Huang,
  • Brian T Fisher,
  • Richard Aplenc

DOI
https://doi.org/10.1371/journal.pone.0192529
Journal volume & issue
Vol. 13, no. 2
p. e0192529

Abstract

Read online

PurposeA cohort of pediatric patients with AML treated at hospitals contributing to the Pediatric Health Information System was used to evaluate differences in opioid utilization by sex, age, race, and insurance.MethodsBilling data were used to compute the prevalence of opioid exposure and to quantify rates of utilization among those exposed to opioids as days of use per 1000 inpatient days. Multivariable regressions were used to compare opioid prevalence, and rates of utilization among those exposed.ResultsOn average across courses, 95.2% of patients were exposed to analgesics, 84.7% were exposed to non-opioid analgesics and 77.7% were exposed to opioids. The proportion of opioid-exposed patients increased with age, but did not differ by gender, race, or insurance status. Analyses limited to patients exposed to opioids revealed modest differences in days of opioid use among female patients (adjusted rate ratio (aRR) = 1.19, 95% CI: 1.11, 1.28), patients ConclusionAdditional work is needed to discern whether observed differences in opioid utilization by age and race reflect a difference in treatment or a difference in the experience of pain. Future studies should also explore the factors which guide decisions on opioid selections in an attempt to explain the variability across institutions.